{"schema_version":"1.0","hypothesis_id":39004,"triple":{"drug":"Auranofin","drug_canonical":"auranofin","mediator":"Nrf2","mediator_canonical":"NRF2","outcome":"chemoresistance","outcome_canonical":null},"domain":{"domain":"cross_domain","source":"rheumatoid_arthritis","target":"pancreatic_cancer"},"provenance_completeness":"partial_backfill","completeness_notes":"Backfilled retroactively from DB state on 2026-05-13. The pipeline_run this row references was created by the backfill script, not by the actual generation orchestrator. Source papers, claims, scoring, and embedding config are recovered; generation-time metadata (exact git commit at gen time, host, exact command) is not recoverable.","source_papers":[{"doi":"10.3390/biomedicines11092502","pmid":"37760943","year":2023,"roles":["drug_mediator"],"title":"Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE","journal":"Biomedicines","work_id":292350,"publication_date":"2023-09-10"},{"doi":"10.1136/jitc-2021-004458","pmid":"35738800","year":2022,"roles":["drug_mediator"],"title":"Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress","journal":"J Immunother Cancer","work_id":286778,"publication_date":"2022-06-01"},{"doi":"10.3390/antiox10050632","pmid":"33919055","year":2021,"roles":["drug_mediator"],"title":"Auranofin-Mediated NRF2 Induction Attenuates Interleukin 1 Beta Expression in Alveolar Macrophages","journal":"Antioxidants (Basel)","work_id":290187,"publication_date":"2021-04-21"},{"doi":"10.1016/j.redox.2021.102184","pmid":"34788728","year":2021,"roles":["drug_mediator"],"title":"Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin","journal":"Redox Biol","work_id":286937,"publication_date":"2021-11-11"},{"doi":"10.1158/0008-5472.can-19-1363","pmid":"31911550","year":2020,"roles":["mediator_outcome"],"title":"Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers","journal":"Cancer Res","work_id":70170,"publication_date":"2020-01-07"},{"doi":"10.1016/j.redox.2019.101131","pmid":"30735911","year":2019,"roles":["mediator_outcome"],"title":"Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway","journal":"Redox Biol","work_id":71346,"publication_date":"2019-01-30"}],"source_paper_count":6,"extracted_claims":[{"side":"drug_mediator","object":"Nrf2","context":"in human cytotoxic lymphocytes","subject":"Auranofin","work_id":286778,"claim_id":208141,"polarity":"positive","predicate":"activates","confidence":0.95,"extraction_run_id":29},{"side":"drug_mediator","object":"Nrf2","context":"in mouse B16 melanoma and LLC lung adenocarcinoma cells","subject":"auranofin","work_id":286937,"claim_id":208521,"polarity":"positive","predicate":"activates","confidence":0.8,"extraction_run_id":29},{"side":"drug_mediator","object":"NRF2","context":"in murine alveolar macrophages (MH-S)","subject":"auranofin","work_id":290187,"claim_id":220933,"polarity":"positive","predicate":"induces","confidence":0.9,"extraction_run_id":29},{"side":"drug_mediator","object":"Nrf2","context":"in peripheral immune cells and CNS in a mouse model of relapsing-remitting EAE","subject":"auranofin","work_id":292350,"claim_id":229940,"polarity":"positive","predicate":"activates","confidence":0.9,"extraction_run_id":29},{"side":"mediator_outcome","object":"chemoresistance","context":"in KRAS-driven pancreatic cancers","subject":"NRF2","work_id":70170,"claim_id":59703,"polarity":"positive","predicate":"causes","confidence":0.9,"extraction_run_id":17},{"side":"mediator_outcome","object":"chemoresistance","context":"in pancreatic ductal adenocarcinoma","subject":"Nrf2","work_id":71346,"claim_id":62701,"polarity":"positive","predicate":"associated_with","confidence":0.8,"extraction_run_id":17}],"extracted_claim_count":6,"extraction":{"model":"deepseek-v4-flash","model_source":"configured","prompt_version":"v1_2026_05_07","run_ids":[17,29]},"bridge":{"a_to_b_predicate":"activates","b_to_c_predicate":"causes","a_to_b_evidence_count":4,"b_to_c_evidence_count":2,"edge_support_log_ab":1.6094379124341003,"edge_support_log_bc":1.0986122886681098,"novelty_factor":1.0,"direct_a_to_c_count":0},"embedding":{"model":"bge-m3","dim":1024,"max_length":8192,"similarity_scores":{}},"scoring":{"method":"swanson_abc_log_evidence_with_novelty_penalty","formula":"score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)","score_raw":0.270805020110221,"score":0.4062075301653315,"quality_tier":"high","quality_reason":null},"pipeline_run":{"id":4,"run_uuid":"eb8b7730-d92e-4cd5-95dd-95f6c5d62cc2","command":"scripts/backfill_provenance_v2.py:v2_2026_05_12","status":"completed","git_commit":"9996ffaa56e9b7cd5f677bd8203624c2c18aa000","host":"MacBook-Pro-Daniel96.local","started_at":"2026-05-12T21:35:53.363326+00:00","ended_at":"2026-05-12T21:43:41.903387+00:00","notes":"Retroactive provenance backfill on 2026-05-13 for snapshot v2_2026_05_12. Synthetic pipeline_runs row — original generation run records are lost (pre-date provenance schema). All recoverable fields populated from current DB state (claims, works, repurposing_hypotheses); pipeline_run record is synthetic, hence completeness='partial_backfill'.\nBackfilled 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.","domains":["als","alzheimer","depression","epilepsy","glioblastoma","inflammatory_bowel_disease","multiple_sclerosis","pancreatic_cancer","rheumatoid_arthritis","type_2_diabetes"]},"generated_at":"2026-05-12T21:43:40.945575+00:00"}